Sawai Group Holdings Co (4887) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
31 Jul, 2026Executive summary
Revenue increased 6.7% year-on-year to JPY 201,676 million, driven by higher sales of new and existing products, especially those under the selective treatment system introduced in October 2024.
Core operating profit declined 3.6% year-on-year, while operating profit surged 292.5% to JPY 15,894 million due to the absence of prior year litigation provisions.
Profit attributable to owners fell 12.8% year-on-year to JPY 10,438 million, impacted by impairment losses and discontinued U.S. operations.
The U.S. business was fully divested in April 2024, with related gains recognized in FY2025 and losses in FY2026.
The group is executing a medium-term plan focused on generics market growth, sustainability, and digital healthcare expansion.
Financial highlights
FY2025 revenue reached JPY 201.676 billion (+6.7% YoY), gross profit was JPY 58.793 billion (+4.3% YoY), and core operating profit was JPY 24.778 billion (-3.6% YoY).
Operating profit was JPY 15.894 billion (+292.5% YoY); profit attributable to owners was JPY 10.438 billion (-12.8% YoY); EPS was JPY 90.39 (-6.4% YoY).
Cash and cash equivalents at year-end decreased to JPY 28,989 million.
Equity attributable to owners rose to JPY 178,556 million, with a ratio to total assets of 49.6%.
EBITDA (adjusted) for FY2025 was JPY 38,315 million (-2.0% YoY); forecasted at JPY 44,700 million for FY2026 (+16.7% YoY).
Outlook and guidance
FY2026 revenue forecast at JPY 208.4 billion (+3.3% YoY), core operating profit at JPY 29.6 billion (+19.5% YoY), operating profit at JPY 27.2 billion (+71.1% YoY), and net profit at JPY 18.6 billion (+78.2% YoY).
FY2026 expects improved gross margin from a better product mix and higher sales of new products, with production volume targeted at 18.0 billion tablets.
Annual dividend for FY2026 is projected at JPY 56 per share, up from JPY 55 in FY2025.
Profitability is expected to improve due to new product launches, but cost pressures from energy, inflation, and yen depreciation remain.
Latest events from Sawai Group Holdings Co
- Aims for 25%+ generics share, 25B tablet capacity, and JPY 220B–310B revenue by 2026–2030.4887
Status update31 Jul 2026 - Revenue up 6.9%, profits down on litigation; strong recovery and higher dividend forecast.4887
Q4 202531 Jul 2026 - Profit soared on U.S. business sale; growth expected from new products and production expansion.4887
Q2 202531 Jul 2026 - Revenue up 12.5% YoY, profit down on settlement and U.S. exit; outlook revised upward.4887
Q2 202631 Jul 2026 - Double-digit revenue and profit growth offset by lower net profit after U.S. business exit.4887
Q1 202631 Jul 2026 - Profit surged on U.S. business sale and robust domestic operations, with focus on Japan generics.4887
Q1 202531 Jul 2026 - Profit and margins rose sharply after U.S. exit, with strong growth and improved supply stability.4887
Q3 202531 Jul 2026 - Revenue up 8.1% YoY, but profit down 57.8%; FY2026 outlook projects strong recovery.4887
Q3 202631 Jul 2026